Results 131 to 140 of about 910,008 (206)

Epigenetic Regulation Of Gene Expression Domains In Pluripotent Stem Cells

, 2009
Transcriptional and histone modification profiles were analysed in detail across several regions of the mouse genome in order to examine how tissue-specificity is determined at early stages of development and how it is maintained during cell ...
Nikic, Svetlana, Nikic, Svetlana
core   +1 more source

A CLIP on the Ear: Spitz Melanocytoma Harbouring a CLIP2-BRAF Gene Fusion

Case Reports in Dermatological Medicine, Volume 2026, Issue 1, 2026.
Spitzoid lesions represent one of the most challenging areas in melanocytic pathology. Many such lesions are characterised by key gene alterations including ALK, ROS and NTRK fusions. BRAF mutations are generally considered incompatible with the diagnosis of Spitz tumours. Here, we present the case of a spitzoid melanocytoma harbouring a rare BRAF gene
Karwan A. Moutasim, Mohammed Atweh, Jeffery M. Theaker, Pedro Rodriguez Jimenez   +3 more
wiley   +1 more source

Radioresistant but Alectinib‐Responsive Isolated Intramedullary ALK‐Positive Histiocytosis

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
A 56‐year‐old woman with a history of C4–C5 myelomeningocele repair as a newborn and cervical syringomyelia presented with one week of rapidly worsening bilateral lower extremity weakness and numbness, saddle anesthesia, and bladder incontinence. MRI of the entire spine revealed a 1.5 × 0.5 cm homogenously enhancing intramedullary lesion at T7–T8 with ...
Joshua Van Allen, David Raggay, Brendan Killory, Joseph DiGiuseppe, Mark Dailey, Carlos Cruz-Montecinos   +5 more
wiley   +1 more source

10171- MPC-16 SCREENING OF NTRK FUSION IN JAPANESE CENTRAL NERVOUS SYSTEM TUMORS [PDF]

Neurooncol Adv
NTRK fusions have been reported to be rare in cancers across various organs, except for certain types of tumors. NTRK fusion positive tumors are reported to be highly sensitive to TRK inhibitors such as Larotrectinib and Entrectinib. It is very important
Tsuyoshi Saito, A. Ura, Karin Ashizawa, T. Hayashi, Takashi Yao   +4 more
europepmc   +2 more sources

Estrogens and stem cells in thyroid cancer [PDF]

, 2014
Recent discoveries highlight the emerging role of estrogens in the initiation and progression of different malignancies through their interaction with stem cell (SC) compartment.
Emanuela eScavo, Giorgio eStassi, Marco eBonanno, Maria Rosa Pelizzo, Mariangela eZane, Mariangela eZane, Matilde eTodaro, Veronica eCatalano   +7 more
core   +2 more sources

RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting

Frontiers in Genetics
IntroductionNTRK1, NTRK2, and NTRK3 gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to
Zachary D. Wallen, Marni Tierno, Erica Schnettler, Alison Roos, Michelle Green, Kobina Amoah, Rebecca A. Previs, Stephanie Hastings, Sarabjot Pabla, Taylor J. Jensen, Brian Caveney, Marcia Eisenberg, Pratheesh Sathyan, Shakti H. Ramkissoon, Shakti H. Ramkissoon, Eric A. Severson   +15 more
doaj   +1 more source

TRKing down drug resistance in NTRK fusion‐positive cancers†

Journal of Pathology
In a recent issue of The Journal of Pathology, Chen and colleagues established novel patient‐derived ex vivo models of NTRK fusion‐positive soft tissue sarcoma to characterize resistance mechanisms against targeted therapy with tyrosine kinase inhibitors.
Abigail G. Parrish, Frank Szulzewsky
semanticscholar   +1 more source

TRLS-09. CONNECT1903: A PILOT AND SURGICAL STUDY OF LAROTRECTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED HGG WITH NTRK FUSION (NCT04655404) [PDF]

Neuro Oncol
BACKGROUND Recurrent fusions in neurotrophic tropomyosin-receptor kinase genes NTRK 1-3 are found in variety of cancers, including pediatric HGG: DIPG (~4%) and non-brainstem HGG (~10%). For non-brainstem HGG seen in children
Susan N Chi, Margot A. Lazow, R. Salloum, Adam Lane, Darren Hargrave, Olaf Witt, P. D. de Blank, Sarah E. S. Leary, Hamza S. Gorsi, Christopher Pierson, John Breneman, Jeremy Jones, Edward Yang, Leonie Mikael, David T. W. Jones, M. Fouladi   +15 more
europepmc   +2 more sources

Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers [PDF]

, 2018
Background: Comprehensive mutational profiling data now available on all major cancers have led to proposals of novel molecular tumor classifications that modify or replace the established organ- and tissue-based tumor typing.
Heim, Daniel, Hufnagl, Peter, Klauschen, Frederick, Montavon, Grégoire, Müller, Klaus-Robert   +4 more
core   +6 more sources

NTRK fusions in osteosarcoma are rare and non‐functional events

The Journal of Pathology: Clinical Research, 2020
Neurotrophic tyrosine receptor kinase (NTRK) fusions are promising molecular targets that have been described in a broad range of malignant tumours. Fusions commonly lead to the expression of chimeric proteins with constitutive tyrosine kinase activation
Baptiste Ameline, Karim H Saba, Michal Kovac, Linda Magnusson, Olaf Witt, Stefan Bielack, Michaela Nathrath, Karolin H Nord, Daniel Baumhoer   +8 more
doaj   +1 more source